SVB Leerink
Prometheus Biosciences Prices Upsized $190M IPO
The company is focused on developing and commercializing therapeutic and companion diagnostic products to treat inflammatory bowel disease.
First Analysis Upgrades NeoGenomics to Strong Buy After Stock Dips
The company's Q4 revenues exceeded Wall Street estimates and the clinical genetic testing and pharma services businesses outperformed expectations.
Investment Banks Initiate Coverage of Centogene With Bullish Outlooks
BTIG gave Centogene a Buy rating, while SVB Leerink and Evercore ISI each gave the company an Outperform rating.
Veracyte Prices $51.3M Public Offering
Veracyte will offer 5 million shares at $10.25 per share. It has granted underwriters an option to purchase an additional 750,000 shares.
Leerink Upgrades T2 Biosystems to To Outperform
The investment bank previously had a Market Perform rating for the company, and it increased the price target on T2 Bio's stock to $12 from $5 per share.